- Home
- MOLN vs ABOS Comparison
MOLN vs ABOS Comparison
Compare MOLN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | ABOS |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 155.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOLN | ABOS |
|---|---|---|
| Price | $4.32 | $3.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.38 | $7.50 |
| AVG Volume (30 Days) | 2.9K | ★ 289.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $318.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.36 | $0.86 |
| 52 Week High | $5.36 | $3.50 |
Technical Indicators
Market Signals| Indicator | MOLN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 67.38 |
| Support Level | $3.50 | $1.21 |
| Resistance Level | $4.63 | N/A |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 25.40 | 78.26 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.